Name | N'-[3-[(1S)-1-(3-fluoro-4-phenylphenyl)ethyl]-1,2-oxazol-5-yl]morpholine-4-carboximidamide |
---|---|
Synonyms |
Rimacalib
SMP 114 4-Morpholinecarboximidamide,N-(3-((1S)-1-(2-fluoro(1,1'-biphenyl)-4-yl)ethyl)-5-isoxazolyl) UNII-BZ76J3N815 |
Description | Rimacalib is a Ca2+/calmodulin-dependent protein kinase II (CaMKII) inhibitor, with IC50s of ~1 μM for CaMKIIα to ~30 μM for CaMKIIγ. |
---|---|
Related Catalog | |
Target |
CaMKIIα:1 μM (IC50) CaMKIIγ:30 μM (IC50) |
In Vitro | Rimacalib (SMP-114) improves (by ~40%) Ca2+-transient potentiation during the 30 s stimulation pause, higher Fura-2 transient amplitude after the pause upon Rimacalib vs. 37.2±4.3% in control, n=60/17 cells/mice vs. n=65/17, p<0.05) and in parallel cardiomyocyte contractility (135.0±15.4% vs. 97.2±16% increase of twitch amplitude, p=0.098)[1]. |
Cell Assay | Cardiomyocytes from mice are pre-incubated with Rimacalib (10 μM) for at least 15 min by including the dye in the loading buffer for Ca2+-fluorescent dyes or by pre-incubation in experimental solution for 15 min (patch-clamp experiments)[1]. |
References |
Molecular Formula | C22H23FN4O2 |
---|---|
Molecular Weight | 394.44200 |
Exact Mass | 394.18100 |
PSA | 74.38000 |
LogP | 4.42200 |
Storage condition | 2-8℃ |